432 related articles for article (PubMed ID: 32559008)
1. A comparative evaluation of different neuromyelitis optica spectrum disorder sets of criteria.
Papeix C; Beigneux Y; Maillart E; de Seze J; Lubetzki C; Vukusic S; Collongues N; Marignier R
Eur J Neurol; 2020 Nov; 27(11):2250-2256. PubMed ID: 32559008
[TBL] [Abstract][Full Text] [Related]
2. Clinical and radiological profile of neuromyelitis optica spectrum disorders in a Pakistani cohort.
Rajput HM; Hassan M; Badshah M
Mult Scler Relat Disord; 2023 Jun; 74():104656. PubMed ID: 37068371
[TBL] [Abstract][Full Text] [Related]
3. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
4. Application of the 2015 neuromyelitis optica spectrum disorders diagnostic criteria in a cohort of Chinese patients.
He M; Wu L; Huang D; Yu S
Mult Scler Relat Disord; 2020 Nov; 46():102459. PubMed ID: 32853894
[TBL] [Abstract][Full Text] [Related]
5. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
Jarius S; Aktas O; Ayzenberg I; Bellmann-Strobl J; Berthele A; Giglhuber K; Häußler V; Havla J; Hellwig K; Hümmert MW; Kleiter I; Klotz L; Krumbholz M; Kümpfel T; Paul F; Ringelstein M; Ruprecht K; Senel M; Stellmann JP; Bergh FT; Tumani H; Wildemann B; Trebst C;
J Neurol; 2023 Jul; 270(7):3341-3368. PubMed ID: 37022481
[TBL] [Abstract][Full Text] [Related]
6. The 2015 IPND Criteria Increases the Yield in Diagnosis of Neuromyelitis Optica Spectrum Disorder in Thai Patients Compared to the 2006 Diagnostic Criteria.
Rattanathamsakul N; Kaveeta C; Siritho S; Thakolwiboon S; Prayoonwiwat N
Mult Scler Relat Disord; 2020 Aug; 43():102218. PubMed ID: 32474289
[TBL] [Abstract][Full Text] [Related]
7. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
[TBL] [Abstract][Full Text] [Related]
8. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
[TBL] [Abstract][Full Text] [Related]
9. The occurrence of myelin oligodendrocyte glycoprotein antibodies in aquaporin-4-antibody seronegative Neuromyelitis Optica Spectrum Disorder: A systematic review and meta-analysis.
Li X; Zhang C; Jia D; Fan M; Li T; Tian DC; Liu Y; Shi FD
Mult Scler Relat Disord; 2021 Aug; 53():103030. PubMed ID: 34118585
[TBL] [Abstract][Full Text] [Related]
10. Neuromyelitis Optica Spectrum Disorders.
Akaishi T; Nakashima I; Sato DK; Takahashi T; Fujihara K
Neuroimaging Clin N Am; 2017 May; 27(2):251-265. PubMed ID: 28391784
[TBL] [Abstract][Full Text] [Related]
11. Clinical and paraclinical profile of neuromyelitis optic spectrum disorder in a peruvian cohort.
Castro-Suarez S; Guevara-Silva E; Osorio-Marcatinco V; Alvarez-Toledo K; Meza-Vega M; Caparó-Zamalloa C
Mult Scler Relat Disord; 2022 Aug; 64():103919. PubMed ID: 35691236
[TBL] [Abstract][Full Text] [Related]
12. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
[TBL] [Abstract][Full Text] [Related]
13. Validation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of South Indian patients.
Kanikannan MA; Arepareddy PK; Mathukumalli NL; Y S; Kandadai RM; Jabeen AS; T S; Borgohain R
Mult Scler Relat Disord; 2019 Oct; 35():164-169. PubMed ID: 31382202
[TBL] [Abstract][Full Text] [Related]
14. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder.
Cai MT; Zheng Y; Shen CH; Yang F; Fang W; Zhang YX; Ding MP
Mult Scler; 2021 May; 27(6):871-882. PubMed ID: 32672091
[TBL] [Abstract][Full Text] [Related]
16. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
Kitley J; Woodhall M; Waters P; Leite MI; Devenney E; Craig J; Palace J; Vincent A
Neurology; 2012 Sep; 79(12):1273-7. PubMed ID: 22914827
[TBL] [Abstract][Full Text] [Related]
17. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.
Jasiak-Zatonska M; Kalinowska-Lyszczarz A; Michalak S; Kozubski W
Int J Mol Sci; 2016 Mar; 17(3):273. PubMed ID: 26950113
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort.
Dauby S; Dive D; Lutteri L; Andris C; Hansen I; Maquet P; Lommers E
Acta Neurol Belg; 2022 Feb; 122(1):135-144. PubMed ID: 34097296
[TBL] [Abstract][Full Text] [Related]
19. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein IgG associated disorder: A comprehensive neuro-ophthalmic review.
Sharma J; Bhatti MT; Danesh-Meyer HV
Clin Exp Ophthalmol; 2021 Mar; 49(2):186-202. PubMed ID: 33426799
[TBL] [Abstract][Full Text] [Related]
20. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes.
Alves Do Rego C; Collongues N
Rev Neurol (Paris); 2018 Jun; 174(6):458-470. PubMed ID: 29685427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
